Apply For a Grant

METAvivor funds research that specifically addresses the mechanistic understanding, diagnosis, and/or treatment of metastatic breast cancer. All individuals with a clinical doctoral degree or with a doctoral degree who are actively engaged in areas of metastatic breast cancer research and treatment are eligible to apply.

2021 Grant Cycle 

Apply Now - LOI DEADLINE EXTENDED

METAvivor Research Award: Up to 2 years, $250,000 award for established investigators.

Application Portal Opens: February 4, 2021
Required Letter of Intent Due: by 11:59 PM ET on March 16, 2021
Invitations to Submit Full Application Sent: on or by May 25, 2021
Invited Applications Due: by 11:59 PM ET on August 20, 2021
Announcement of Awardees: on or by December 4, 2021

METAvivor Early Career Investigator Award: Up to 2 years, $100,000 award available to early career applicants (investigators within 10 years of their degree award date and within 6 years of starting their first non-tenured position if started).

Application Portal Opens: February 4, 2021
Required Letter of Intent Due: by 11:59 PM ET on March 15, 2021
Invitations to Submit Full Application Sent: on or by May 22, 2021
Invited Applications Due: by 11:59 PM ET on August 17, 2021
Announcement of Awardees: on or by December 4, 2021

METAvivor Health Disparities Research Award is a 2-year, $100,000 award. METAvivor has been proactive in advocating for health equity, especially in the Black community. To that end, this special funded research should address the disproportionate negative outcomes for Black people living with metastatic breast cancer. The target areas are listed in the in the request for proposal.

Application Portal Opens: February 4, 2021
Required Letter of Intent Due: by 11:59 PM ET on March 15, 2021
Invitations to Submit Full Application Sent: on or by May 22, 2021
Invited Applications Due: by 11:59 PM ET on August 17, 2021
Announcement of Awardees: on or by December 4, 2021


METAvivor funds research focused on treating established breast cancer metastases to improve outcomes for stage IV metastatic breast cancer patients. We do not fund research that that seeks to prevent or diagnose breast cancer metastasis, or that is focused on improving quality of life.

Thank you for your interest and participation.